Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.
Bartlett JMS, Bayani J, Kornaga E, Xu K, Pond GR, Piper T, Mallon E, Yao CQ, Boutros PC, Hasenburg A, Dunn JA, Markopoulos C, Dirix L, Seynaeve C, van de Velde CJH, Stein RC, Rea D. Bartlett JMS, et al. Among authors: dirix l. NPJ Breast Cancer. 2021 Jul 8;7(1):90. doi: 10.1038/s41523-021-00297-7. NPJ Breast Cancer. 2021. PMID: 34238931 Free PMC article.
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.
van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists; Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW. van Nes JG, et al. Among authors: dirix l. Br J Surg. 2010 May;97(5):671-9. doi: 10.1002/bjs.6962. Br J Surg. 2010. PMID: 20393978
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D. Bartlett JM, et al. Among authors: dirix l. J Clin Oncol. 2011 Apr 20;29(12):1531-8. doi: 10.1200/JCO.2010.30.3677. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422407 Free PMC article. Clinical Trial.
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee. Mieog JS, et al. Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20. Lancet Oncol. 2012. PMID: 22265698 Clinical Trial.
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Fontein DBY, Houtsma D, Hille ETM, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JMS, Nortier JWR, van de Velde CJH; Dutch TEAM Steering Committee. Fontein DBY, et al. Among authors: dirix ly. Ann Oncol. 2012 Dec;23(12):3091-3097. doi: 10.1093/annonc/mds204. Epub 2012 Aug 2. Ann Oncol. 2012. PMID: 22865782 Free article.
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ. van de Water W, et al. Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3. Eur J Cancer. 2013. PMID: 22954666 Free article. Clinical Trial.
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.
Bartlett JM, Bloom KJ, Piper T, Lawton TJ, van de Velde CJ, Ross DT, Ring BZ, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D. Bartlett JM, et al. Among authors: dirix l. J Clin Oncol. 2012 Dec 20;30(36):4477-84. doi: 10.1200/JCO.2012.42.8896. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045591 Clinical Trial.
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.
Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Bartlett JM, et al. Among authors: dirix ly. Br J Cancer. 2013 Oct 29;109(9):2453-61. doi: 10.1038/bjc.2013.609. Epub 2013 Oct 3. Br J Cancer. 2013. PMID: 24091623 Free PMC article. Clinical Trial.
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.
Stephen J, Murray G, Cameron DA, Thomas J, Kunkler IH, Jack W, Kerr GR, Piper T, Brookes CL, Rea DW, van de Velde CJ, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, Bartlett JM. Stephen J, et al. Among authors: dirix l. Br J Cancer. 2014 Dec 9;111(12):2242-7. doi: 10.1038/bjc.2014.530. Epub 2014 Oct 14. Br J Cancer. 2014. PMID: 25314051 Free PMC article.
443 results